ARTICLE SUMMARY:
Medtech dealmakers need to be both disciplined and agile to navigate ongoing regulatory and geopolitical volatility, according to PwC advisors who offered their midyear perspective on the state of the medtech investing environment.
M&A activity in the medtech sector remains robust heading into the second half of 2025 despite the ongoing challenges created by regulatory uncertainty and international trade barriers, according to PwC’s midyear deals outlooks for life sciences and health services (see Figure 1).
